<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1396r–8" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1396r–8/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1396r–8/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1396r_8"><akn:num>1396r–8</akn:num><akn:heading>Payment for covered outpatient drugs</akn:heading><akn:content><akn:p>§ 1396r–8. Payment for covered outpatient drugs(a) Requirement for rebate agreement(1) In generalIn order for payment to be available under section 1396b(a) of this title or under part B of subchapter XVIII for covered outpatient drugs of a manufacturer, the manufacturer must have entered into and have in effect a rebate agreement described in subsection (b) with the Secretary, on behalf of States (except that, the Secretary may authorize a State to enter directly into agreements with a manufacturer), and must meet the requirements of paragraph (5) (with respect to drugs purchased by a covered entity on or after the first day of the first month that begins after November 4, 1992) and paragraph (6). Any agreement between a State and a manufacturer prior to April 1, 1991, shall be deemed to have been entered into on January 1, 1991, and payment to such manufacturer shall be retroactively calculated as if the agreement between the manufacturer and the State had been entered into on January 1, 1991. If a manufacturer has not entered into such an agreement before March 1, 1991, such an agreement, subsequently entered into, shall become effective as of the date on which the agreement is entered into or, at State option, on any date thereafter on or before the first day of the calendar quarter that begins more than 60 days after the date the agreement is entered into.


(2) Effective dateParagraph (1) shall first apply to drugs dispensed under this subchapter on or after January 1, 1991.


(3) Authorizing payment for drugs not covered under rebate agreementsParagraph (1), and section 1396b(i)(10)(A) of this title, shall not apply to the dispensing of a single source drug or innovator multiple source drug if (A)(i) the State has made a determination that the availability of the drug is essential to the health of beneficiaries under the State plan for medical assistance; (ii) such drug has been given a rating of 1–A by the Food and Drug Administration; and (iii)(I) the physi</akn:p></akn:content><akn:subsection eId="subsec_1396r_8_a"><akn:num>(a)</akn:num><akn:heading>Requirement for rebate agreement</akn:heading><akn:content><akn:p>(a) Requirement for rebate agreement</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_b"><akn:num>(b)</akn:num><akn:heading>Terms of rebate agreement</akn:heading><akn:content><akn:p>(b) Terms of rebate agreement</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_c"><akn:num>(c)</akn:num><akn:heading>Determination of amount of rebate</akn:heading><akn:content><akn:p>(c) Determination of amount of rebate</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_d"><akn:num>(d)</akn:num><akn:heading>Limitations on coverage of drugs</akn:heading><akn:content><akn:p>(d) Limitations on coverage of drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_e"><akn:num>(e)</akn:num><akn:heading>Treatment of pharmacy reimbursement limits</akn:heading><akn:content><akn:p>(e) Treatment of pharmacy reimbursement limits</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_f"><akn:num>(f)</akn:num><akn:heading>Survey of retail prices; State payment and utilization rates; and performance rankings</akn:heading><akn:content><akn:p>(f) Survey of retail prices; State payment and utilization rates; and performance rankings</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_g"><akn:num>(g)</akn:num><akn:heading>Drug use review</akn:heading><akn:content><akn:p>(g) Drug use review</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_h"><akn:num>(h)</akn:num><akn:heading>Electronic claims management</akn:heading><akn:content><akn:p>(h) Electronic claims management</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_i"><akn:num>(i)</akn:num><akn:heading>Omitted</akn:heading><akn:content><akn:p>(i) Omitted</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396r_8_j"><akn:num>(j)</akn:num><akn:heading>Exemption of organized health care settings</akn:heading><akn:content><akn:p>(j) Exemption of organized health care settings</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>